Login Register Cart 0
Generic placeholder image

Current Alzheimer Research

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Synthesis and Biological Study of 4-Aminopyridine-Peptide Derivatives Designed for the Treatment of Neurodegenerative Disorders

Author(s): Lyubomir T. Vezenkov*, Daniela S. Tsekova*, Ivanka Kostadinova, Rositsa Mihaylova, Valentin Lozanov, Nikolay G. Vassilev, Nikolai Danchev, Ivanka Tsakovska and Ilza Pajeva

Volume 20, Issue 2, 2023

Published on: 06 June, 2023

Page: [120 - 129] Pages: 10

DOI: 10.2174/1567205020666230602142012

Price: $65

Abstract

Background: Alzheimer’s disease (AD) and Multiple sclerosis (MS) lead to neurodegenerative processes negatively affecting millions of people worldwide. Their treatment is still difficult and practically incomplete. One of the most commonly used drugs against these neurodegenerative diseases is 4-aminopyridine. However, its use is confined by the high toxicity.

Objectives: The aim of this work is to obtain new peptide derivatives of 4-aminopyridine with decreased toxicity compared to 4-aminopyridine.

Methods: Synthesis was conducted in solution using a consecutive condensation approach. The new derivatives were characterized by melting points, NMR, and Mass spectra. Important ADME (absorption, distribution, metabolism, and excretion) properties have been studied in silico using ACD/Percepta v.2020.2.0 software. Acute toxicity was determined in mice according to a Standard protocol. All new derivatives were tested in vitro for cytotoxic activity in a panel of human (HEP-G2, BV-173) and murine (NEURO 2A) tumor cell lines via a standard MTT-based colorimetric method. β-secretase inhibitory activity was determined by applying the fluorescent method.

Results: New derivatives of 4-aminopyridine containing analogues of the β-secretase inhibitory peptide (Boc-Val-Asn-Leu-Ala-OH) were obtained. The in vivo toxicity of the tested compounds was found to be as high as 1500 mg/kg. Cell toxicity screening against tumor cell lines of different origins showed negligible growth-inhibitory effects of all investigated 4-aminopyridine analogues.

Conclusion: Synthesis of new peptide derivatives of 4-aminopyridine is reported. Acute toxicity studies revealed a ca. 150 times lower toxicity of the new compounds as compared to 4-aminopyridine that may be ascribed to their peptide fragment.

« Previous Next »
[1]
a) Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci 1991; 12(10): 383-8.
[http://dx.doi.org/10.1016/0165-6147(91)90609-V] [PMID: 1763432];
b) Mudher A, Lovestone S. Alzheimer’s disease-do tauists and baptists finally shake hands? Trends Neurosci 2002; 25(1): 22-6.
[http://dx.doi.org/10.1016/S0166-2236(00)02031-2] [PMID: 11801334]
[2]
a) St George-Hyslop PH. Genetic factors in the genesis of Alzheimer’s disease. Ann N Y Acad Sci 2000; 924(1): 1-7.
[http://dx.doi.org/10.1111/j.1749-6632.2000.tb05552.x] [PMID: 11193785];
b) Moncsor M. Diagnosis and treatment of Alzheimer’s disease. Curr Med Chem 2005; 5(1): 5-13.
[3]
Vassar R. BACE1: The beta-secretase enzyme in Alzheimer’s disease. J Mol Neurosci 2004; 23(1-2): 105-14.
[http://dx.doi.org/10.1385/JMN:23:1-2:105] [PMID: 15126696]
[4]
Ivanov I, Danalev DL, Vezenkov LT. New peptide mimetics with potential β-secretase inhibition activity. Izv Him 2009; 41(2): 143-8.
[5]
a) Ivanov I, Vezenkov L, Danalev D. New peptide analogues of beta-secretase inhibitor OM 99-2, modified in P3-position. Collect Czech Chem Commun 2009; 11: 47-50.;
b) Ivanov I, Danalev D, Vezenkov L. Design and synthesis of new peptide mimetics with potential β-secretase inhibition activity. The Proceedings of the 30-th European Peptide Symposium; 2008 Aug 31 – Sep 5; Helsinki, Finland. 240-1.
[6]
Chaudhuri A. Multiple sclerosis is primarily a neurodegenerative disease. J Neural Transm (Vienna) 2013; 120(10): 1463-6.
[http://dx.doi.org/10.1007/s00702-013-1080-3] [PMID: 23982272]
[7]
Raine CS. Multiple sclerosis: Immune system molecule expression in the central nervous system. J Neuropathol Exp Neurol 1994; 53(4): 328-37.
[http://dx.doi.org/10.1097/00005072-199407000-00002] [PMID: 8021705]
[8]
Prineas J, McDonald W. Demyelinating diseases. In: Graham D, Lantos P, Eds Greenfield’s neuropathology. New York: Oxford University Press 1997; pp. 813-96.
[9]
Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359(9313): 1221-31.
[http://dx.doi.org/10.1016/S0140-6736(02)08220-X] [PMID: 11955556]
[10]
Weinstock-Guttman B, Ramanathan M, Zivadinov R. Interferon-beta treatment for relapsing multiple sclerosis. Expert Opin Biol Ther 2008; 8(9): 1435-47.
[http://dx.doi.org/10.1517/14712598.8.9.1435] [PMID: 18694361]
[11]
Arnon R. The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: Personal reflections. Immunol Lett 1996; 50(1-2): 1-15.
[http://dx.doi.org/10.1016/0165-2478(96)02506-0] [PMID: 8793553]
[12]
Savin Z, Lejbkowicz I, Glass-Marmor L, Lavi I, Rosenblum S, Miller A. Effect of Fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with Multiple Sclerosis. J Neurol Sci 2016; 360: 102-9.
[http://dx.doi.org/10.1016/j.jns.2015.11.035] [PMID: 26723984]
[13]
Li Y, Hai S, Zhou Y, Dong BR. Cholinesterase inhibitors for rarer dementias associated with neurological conditions. Cochrane Database Syst Rev 2015; 3(3): CD009444.
[http://dx.doi.org/10.1002/14651858.CD009444.pub3] [PMID: 25734590]
[14]
Fampyra, INN-Fampridine. Summary of product characteristics, EMA. 2017. Available from: https://www.ema.europa.eu/en/documents/variation-report/fampyra-h-c-2097-ii-0036-g-epar-assessment-report-variation_en.pdf
[15]
Schafer EW Jr, Brunton RB, Cunningham DJ. A summary of the acute toxicity of 4-aminopyridine to birds and mammals. Toxicol Appl Pharmacol 1973; 26(4): 532-8.
[http://dx.doi.org/10.1016/0041-008X(73)90291-3] [PMID: 4771602]
[16]
Kostadinova I, Landzhov B, Danchev N, Vezenkov L, Oskar A. Effect of 4-aminopyridine and newly synthesised original 4-aminopyridine derivativeson on cuprizone-induced demyelination of corpus callosum in mice. Compt Rend Acad Bulg Sci 2020; 73(8): 1139-44.
[17]
Kostadinova I, Danchev N, Nikolova I, Vezenkov L. Ivanov Tch. Effects of 4-aminopyridine derivatives with a peptide molety on scopolamine-induced memory impairment in mice. Pharmacia 2017; 64(3): 22-30.
[18]
Vezenkov L, Anchev B, Fidanov K, Tsekova DS, Kostadinova I. New 4-Aminopyridine derivatives containing peptide fragment designed for the treatment of Alzheimer disease and multiple sclerosis, Peptides. Proceedings of the 35-th European Peptide Symposium 35th European Peptide Symposium. 2018 Aug 26-31; Ireland Dublin City University. 2018; pp. 241-3.
[19]
López-García J, Lehocký M. Humpolíček P, Sáha P. HaCaT Keratinocytes response on antimicrobial atelocollagen substrates: Extent of cytotoxicity, cell viability and proliferation. J Funct Biomater 2014; 5(2): 43-57.
[http://dx.doi.org/10.3390/jfb5020043] [PMID: 24956439]
[20]
Vezenkov LT, Tsekova DS, Kostadinova I, Mihaylova R, Vassilev NG, Danchev ND. Synthesis of new galanthamine-peptide derivatives designed for prevention and treatment of Alzheimer’s disease. Curr Alzheimer Res 2019; 16(3): 183-92.
[http://dx.doi.org/10.2174/1567205016666190228123923] [PMID: 30819081]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy